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Abstract
Background/aims: Polycystic ovary syndrome (PCOS) is associated with insulin resistance, 
adrenal hyperactivity and decreased mental health. We aimed to investigate the changes 
in adrenal activity, metabolic status and mental health in PCOS during treatment with 
escitalopram or placebo.
Methods: Forty-two overweight premenopausal women with PCOS and no clinical 
depression were randomized to 12-week SSRI (20 mg escitalopram/day, n = 21) or 
placebo (n = 21). Patients underwent clinical examination, fasting blood samples, 
adrenocorticotroph hormone (ACTH) test, 3-h oral glucose tolerance test (OGTT) and 
filled in questionnaires regarding mental health and health-related quality of life 
(HRQoL): WHO Well-Being Index (WHO-5), Major Depression Inventory (MDI), Short Form 
36 (SF-36) and PCOS questionnaire.
Results: Included women were aged 31 (6) years (mean (s.d.)) and had body mass index 
(BMI) 35.8 (6.5) kg/m2 and waist 102 (12) cm. Escitalopram was associated with increased 
waist (median (quartiles) change 1 (0; 3) cm), P = 0.005 vs change during placebo and 
increased cortisol levels (cortisol 0, cortisol 60, peak cortisol and area under the curve 
for cortisol during ACTH test), all P < 0.05 vs changes during placebo. Escitalopram had 
no significant effect on measures of insulin sensitivity, insulin secretion, fasting lipids, 
mental health or HRQoL.
Conclusion: Waist circumference and cortisol levels increased during treatment with 
escitalopram in women with PCOS and no clinical depression, whereas metabolic risk 
markers, mental health and HRQol were unchanged.
Introduction
Polycystic ovary syndrome (PCOS) is a common 
endocrine disorder characterized by insulin resistance and 
hyperandrogenism (1). Central obesity is closely associated 
with insulin resistance and low-grade inflammation (2) 
and obesity predicts the development of type 2 diabetes 
mellitus in PCOS (3). Furthermore, obesity predicted poor 
quality of life in women with PCOS (4), and the risk of 
depression was 2–5 times increased in PCOS (5, 6). PCOS is 
characterized by increased ovarian and adrenal androgen 
production (1). Adrenocorticotropic hormone (ACTH)-
stimulated cortisol and 17-hydroxyprogesterone levels 
(17OHP) and urinary cortisol secretion were increased in 
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women with PCOS vs controls (7, 8), suggesting increased 
hypothalamic–pituitary–adrenal (HPA) axis activity 
in PCOS. Increased adrenal activity was also found in 
patients with major depression and their first-degree 
relatives compared to healthy controls (9, 10). Therefore, 
decreased quality of life in PCOS could be associated with 
increased HPA activity (11).
Treatment with specific serotonin reuptake inhibitor 
(SSRI) is the first choice for depression and 16.3% Danish 
women with PCOS had prescriptions of antidepressants 
(6). The possible effects of SSRI on cortisol secretion, mental 
health and metabolic risk in PCOS are undetermined (12). 
Three-month treatment with escitalopram normalized 
cortisol secretion and improved insulin sensitivity in 
young healthy men with low birth weight (<2500 g) 
(13). Included men were insulin resistant and had high 
cortisol levels (13). In women, low birth weight increased 
the risk of elevated adrenal activity and development of 
PCOS (14). A meta-analysis found improved glycemic 
control in patients with type 2 diabetes and depression 
that were treated with antidepressants (15). Improved 
insulin sensitivity during treatment with SSRI in PCOS 
could affect the PCOS phenotype and could be associated 
with more regular menstrual cycles. We are not aware of 
previous studies testing this hypothesis.
The aim of the present study was to investigate the 
effect of 12-week escitalopram vs placebo treatment on 
adrenal activity, mental health, metabolic risk and PCOS 
phenotype in overweight women with PCOS and no 
clinical depression.
Materials and methods
Forty-two women with PCOS were included in a 
randomized, double-blind, placebo-controlled trial of 
12-week medical intervention with SSRI (escitalopram 
20 mg) or placebo. The study was conducted during August 
2013 to March 2015 at the Department of Endocrinology, 
Odense University Hospital. Women were recruited from 
the outpatient clinic of the Department of Endocrinology 
and Department of Gynecology at Odense University 
Hospital and by advertising.
Inclusion criteria
The study included premenopausal, white women, aged 
18–41 years with PCOS and BMI >25 kg/m2 and <50 kg/m2. 
All women fulfilled at least two of the Rotterdam criteria 
for PCOS: (1) cycle length >35  days or amenorrhea, 
(2) total and/or free testosterone above upper reference 
limit and/or hirsutism (Ferriman–Gallwey score (FG-score) 
≥8) and (3) polycystic ovaries. Secondary etiologies were 
excluded as previously described (16). Health-related 
quality of life (HRQol) is inversely associated with BMI (4) 
and only overweight and obese women were included in 
the study. Included women gave informed consent to use 
barrier control or had an intrauterine device implanted 
during the study period.
Exclusion criteria
Clinical depression, evaluated by questions of depressive 
core symptoms, was an exclusion criterion as treatment 
with SSRI is the first-line treatment in persons with 
depression, and we did not consider allocation to placebo 
treatment possible. Furthermore, exclusion criteria were 
eating disorder, pregnancy, breastfeeding, epilepsy, 
diabetes (fasting plasma glucose ≥7.0 mmol/L or HbA1c 
>6.3%) or contraindications for escitalopram.
Metformin was paused a minimum of 4  weeks and 
oral contraceptives 12 weeks prior to evaluation.
Power calculation
The primary endpoint of the study was change in adrenal 
activity (evaluated by 60 min area under the curve (AUC) 
for ACTH-stimulated cortisol levels) during treatment 
with escitalopram/placebo. The secondary study outcomes 
were changes of insulin sensitivity, insulin secretion, 
fasting lipids, mental health and HRQoL. No previous 
study investigated the effect of antidepressants on cortisol 
levels in PCOS and a power calculation could not be 
performed. Studies on the same number of individuals 
with depression or first-degree relatives to persons with 
depression reported significant changes in adrenal activity 
during antidepressant treatment (17, 18, 19).
Approvals were obtained from the Ethics committee 
at the Region of Southern Denmark (registration 
number: S-20110089) and the Danish Medicine Agency. 
The study was monitored by the local Good Clinical 
Practice unit and was registered at www.clinicaltrials.gov: 
NCT01961180. Consent was obtained from each patient 
after full explanation of the purpose and nature of all 
procedures used.
Study protocol
Patients underwent clinical examination, fasting blood 
samples, pregnancy test, ACTH test and OGTT and 
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answered questionnaires by time of study inclusion and 
the examination program was repeated after 12-week 
intervention. Telephone calls were performed at weeks 
2 and 6 to check for compliance and side effects. After 
study inclusion and initial examinations, the patients 
were randomized 1:1 to escitalopram or placebo. The 
participants received 10 mg escitalopram during the first 
week of the study and the dosage was then increased to 
20 mg during the remaining study period. The participants 
down-titrated escitalopram with 10 mg the first week after 
study termination. Randomization was performed by 
our hospital pharmacy, which carried out packaging and 
labeling of escitalopram and placebo.
Physical examination included height, weight, waist 
circumference, FG score and transvaginal ultrasound 
ACTH test was performed at 8.00 o’clock in the follicular 
phase (cycle days 2–8) in women with a cycle length 
shorter than three months. In women with cycle length 
longer than three months, ACTH test was performed on a 
random day. An intravenous bolus of 0.25 mg Synacthen 
(Novartis Healthcare) was administered and cortisol and 
17OHP levels were measured at 0, 30 and 60 min. The 
maximum cortisol and 17OHP levels during the test were 
defined as peak levels. Area under the curve for cortisol 
and 17OHP was calculated applying the trapezium rule.
A 3-h (h) OGTT was performed at 8:00 o’clock after 
overnight fasting on a random day of the menstrual cycle. 
Insulin, C-peptide and blood glucose (BG) were measured 
at 0, 30, 60, 90, 120 and 180 min after oral ingestion of a 
glucose load containing the equivalent of 75 g anhydrous 
glucose dissolved in water.
Questionnaires
Mental health assessment
Mental health assessments included the 5-item World 
Health Organization Well-Being Index (WHO-5), the MDI 
and UKU (Udvalg for Kliniske Undersøgelser). WHO-5 
is a general questionnaire regarding mental health (20) 
and contains five positively phrased items scored from 
0 to 5 with higher scores indicating greater well-being. 
The summed score is multiplied by 4 to translate to 
percentage. Scores can be rated to risk: 0–35, high risk of 
depression; 36–50, risk of depression and >50 no risk of 
depression (20). MDI is a validated depression inventory 
for screening and diagnosis of depression since it covers 
the ICD 10 criteria for depression (21). MDI contains 12 
items with a total score range from 0 to 50 and higher 
scores indicate more severe depression (21). Patients 
were regarded as responders to medical treatment if 
MDI-total scores improved >50%. UKU is a global rating 
questionnaire regarding side effects to SSRIs, containing 
11 questions with range from zero to three (22).
HRQoL assessment
HRQoL assessments included Short Form-36 (SF-36) and 
a disease-specific PCOS questionnaire (PCOSQ). SF-36 
contains 36 questions grouped into eight domains: 
Physical function (PF), physical role limitation (RP), 
bodily pain (BP), general health (GH), vitality (VT), social 
function (SF), emotional role function (RE) and mental 
health (MH) (23). Domains were scored from 0 to 100 
with higher scores indicating better functioning and QoL. 
PCOSQ involved 24 items grouped into five domains: 
Emotions, body hair, weight, infertility problems and 
menstrual problems (24). Each item was answered in a 
seven-point rating scale with higher points indicating 
better functioning. Each domain value was reported as 
the mean value from the items involved (24).
Biochemical assays
Plasma total testosterone was analyzed by liquid 
chromatography tandem mass spectrometry. Free 
Androgen Index (FAI) was calculated as (total testosterone/
SHBG) × 100. SHBG was analyzed by a time-resolved 
flouroimmunoassay using a commercial kit (AutoDelfia, 
Wallac Oy, Turku, Finland). Intra-assay variation was 5.2% 
and inter-assay variation was 7.5%. Cortisol was analyzed 
by time-resolved flouroimmunoassay using commercial 
kit (AutoDelfia, Wallac Oy, Turku, Finland). Intra-assay 
variation was 2.7–3.6% and inter-assay variation was 
0.8–1.9%. 17OHP was analyzed by radioimmunoassay 
(RIA) using a commercial kit (Coat-A-Count, Diagnostic 
Products Corporation, Los Angeles). Intra- and inter-
assay variations were 3.5–7.1% and 5.0–11%, respectively. 
BG was measured with a Hemocue device (Hemocue, 
Ängelholm, Sweden), which converted BG concentrations 
to equivalent plasma glucose concentrations (25). The 
meter was checked with a control cuvette every day and a 
hemolysate every 1–2 weeks. Serum C-peptide and serum 
insulin were analyzed by an electrochemiluminescence 
immunoassay (ECLIA, Cobas e411, Roche), intra-assay 
CVs were between 0.8 and 4.6% and inter-assay CVs were 
between 1.8 and 5.0%. Plasma total cholesterol, high-
density lipoprotein (HDL), cholesterol and triglyceride 
(TG) were analyzed by enzymatic colorimetric reactions 
(Modular P, Roche), and low-density lipoprotein (LDL) 
cholesterol was calculated using the Friedewald equation.
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Insulin resistance
The homeostatic model assessment insulin resistance 
index (HOMA-ir) was calculated as (fasting plasma 
insulin (U/L) × fasting BG (mmol/L))/22.5 (26). Using 3-h 
OGTT data, peripheral insulin sensitivity was calculated 
as the Matsuda index (10,000/√(fasting plasma insulin 
(U/L) × fasting plasma glucose (mmol/L) × mean plasma 
insulin (U/L) × mean BG (mmol/L))) (27). AUC for insulin, 
C-peptide and BG during the OGTT (2 and 3 h) were 
calculated applying the trapezium rule.
Insulin secretion and beta cell function
Basal insulin secretion was assessed by the homeostatic 
model assessment b-cell function index (HOMA-%B), 
calculated as (fasting plasma insulin (U/L) × 20)/(fasting 
BG (mmol/L) − 3.5) (26). Early glucose-stimulated insulin 
response was calculated as the insulinogenic index (delta 
plasma insulin (U/L) (0–30 min)/delta BG (0–30 min) (28). 
We calculated an OGTT-derived disposition index based 
on Matsuda × insulinogenic index.
Figure 1 presents a flow chart of study participants. Forty-
two women with PCOS were randomized to escitalopram 
or placebo and 39 completed study intervention. Twenty-
two women (12 citalopram + 10 placebo) fulfilled all 
Rotterdam criteria (phenotype A), 15 (7 citalopram + 8 
placebo) had phenotype B (hyperandrogenism and 
oligomenorrhea), two (1 citalopram and 1 placebo) had 
phenotype C (hyperandrogenism and PCO) and none had 
phenotype D (oligomenorrhea and PCO).
Statistics
Continuous variables were described by mean (s.d.) and 
results from HRQoL assessments were described using 
medians and quartiles. Pre-treatment differences between 
patients randomized to escitalopram and placebo were 
tested using the Mann–Whitney U test. Difference in 
prevalence between groups was compared by the chi-
squared test. Changes in outcomes during escitalopram 
vs placebo were tested by comparing delta (Δ) values 
between intervention groups by Mann–Whitney U test. 
Figure 1
Consort flow chart of included and excluded 
subjects and study design.
Screening
(n=62) 
Included
(n=42)
Discontinued intervention 
Pregnancy, n=1 
Regrets, n=1 
Discontinued intervention 
Side effects, n=1 
Analyzed (n=19)Analyzed (n=20)
Escitalopram (n=21) Placebo (n=21)
Screening failure (n=20) 
BMI >50 kg/m2, n=1 
BMI<25 kg/m2, n=1 
Pregnant, n=1  
Not PCOS, n=9   
Medication, n=4  
Regrets, n=4 
Excluded (n=115) 
BMI < 25 or >50 kg/m2
Depression 
Current medical treatment 
Pregnancy wish 
Bariatric surgery 
Epilepsy 
Menopause
Screened by telephone interview (n=177)
Advertisement, n=105
Outpatient clinic, n=70
Other, n=2
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Δ-values were calculated as post-treatment minus pre-
treatment value of each variable.
Multiple regression analyses were performed to 
investigate relationships between changes in cortisol 
levels (dependent variables: Δ-cortisol 0, Δ-cortisol 30, 
Δ-peak cortisol and Δ-AUC cortisol) and pre-treatment 
value of the dependent variable (cortisol 0, cortisol 30, 
peak cortisol or AUC cortisol), medicine group (0 placebo, 
1 escitalopram) and ∆-waist (independent variables). 
Statistics were performed using IBM SPSS Statistics 21. 
Values of P < 0.05 were considered significant.
Results
Clinical and biochemical changes during 
escitalopram and placebo
Waist circumference and cortisol levels (cortisol 0, cortisol 
60, peak cortisol and AUC cortisol) increased significantly 
during escitalopram vs placebo. The median change 
in waist during escitalopram vs placebo was 1 (0; 3) 
cm vs −1 (−2; 0) cm, respectively, P = 0.005. Δ-waist 
>0 cm (increasing waist during intervention) was seen 
in 14/20 women treated with escitalopram and in 4/19 
women treated with placebo, P = 0.004. Δ-waist >2 cm 
was seen in 9/20 women treated with escitalopram and 
in 3/19 women treated with placebo, P = 0.05. BMI, 
Ferriman–Gallwey score, menstrual regularity (regular, 
irregular or amenorrhea) and presence of PCO (yes/no) 
were unchanged during the treatment period. Lipid 
status (cholesterol, triglycerides, LDL and HDL) and 
measures of insulin resistance (HOMA-ir, Matsuda index, 
AUC insulin and AUC C-peptide) and insulin secretion 
(HOMA-%B, insulinogenic index and disposition index) 
were unchanged during study intervention (Table 1).
Mental health and HRQoL
Changes in WHO-5, MDI and PCOSQ scores were 
comparable during escitalopram and placebo. The role 
physical (RP) domain of SF-36 increased during placebo 
(P = 0.04), whereas the remaining domains of SF-36 were 
unchanged (Table 2).
Low WHO-5 scores <50 were in n = 5 pre-treatment 
vs n = 2 post treatment (escitalopram) and in n = 8 pre-
treatment and n = 2 post treatment (placebo), chi test 
P = 0.002. MDI scores consistent with depression were 
not observed in any patients at pre-treatment or after 
intervention.
Multiple regression analyses
Changes in cortisol during study intervention (Δ-cortisol 
0, Δ-cortisol 30, Δ-cortisol 60, Δ-peak cortisol and Δ-AUC 
cortisol) were predicted by pre-treatment cortisol levels 
(cortisol 0, cortisol 30, cortisol 60, peak cortisol and 
AUC cortisol, respectively) in all regression models. 
Intervention group was an independent predictor of 
∆-cortisol 60 and ∆-peak cortisol after correcting for pre-
treatment cortisol levels and ∆-waist, whereas there was 
a trend for intervention group as predictor of ∆-AUC 
cortisol (P = 0.05), ∆-cortisol 30 (P = 0.08) and ∆-cortisol 
0 (P = 0.10). Change in waist circumference during 
intervention (∆-waist) did not predict change in cortisol 
in any of the regression models (Table 3).
Discussion
In the present study, cortisol levels and waist circumference 
significantly increased during escitalopram vs placebo 
treatment in overweight premenopausal women with 
PCOS and no clinical depression, whereas mental health, 
measures of insulin resistance and insulin secretion, and 
fasting lipids were unchanged. To our knowledge, this 
is the first randomized trial regarding HPA axis activity, 
mental health and metabolic risk during treatment with a 
SSRI in women with PCOS. Increased cortisol and 17OHP 
responses during ACTH test is well documented in PCOS 
(7), and we included measurements of 17OHP to determine 
adrenal activity and adrenal androgen production. Our 
findings of increased cortisol levels during escitalopram 
treatment contrasted findings from trials in patients with 
depression and their first-degree relatives (17, 18, 19, 
29). However, findings were not uniform as some studies 
reported unchanged or increased cortisol secretion during 
SSRI treatment in patients with depression (30, 31). We 
could not confirm results from a recent placebo-controlled 
study where 3 months treatment with 20 mg escitalopram 
normalized cortisol levels in healthy men with low 
birth weight (13). However, the study by Buhl et al. (13) 
included lean men (mean BMI 22 kg/m2) and adrenal 
activity was established by 24-h cortisol patterns (10 
cortisol measurements/24 h) instead of a stimulation test. 
High BMI is closely associated with low HRQol in PCOS 
(4), and we therefore included only overweight and obese 
women with PCOS in the present study. Furthermore, 
central and overall obesity is associated with increased 
cortisol secretion (32) and the pathogenesis of PCOS may 
be different in obese compared to lean phenotypes (1).
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We found significantly increased waist circumference 
during escitalopram treatment, but changes in waist were 
not associated with changes in cortisol levels in multiple 
regression analyses. Instead, pre-treatment cortisol 
level was the most important predictor of change in 
cortisol during study intervention. The change in waist 
during study intervention was highly significant, but 
it is possible that the change in waist was too small to 
affect cortisol secretion, and we observed no significant 
changes in BMI. In accordance with our results, Knorr 
and coworkers reported no significant correlations 
between changes in cortisol levels and changes in 
waist or weight in first-degree relatives to patients with 
depression treated with escitalopram (33). Furthermore, 
Buhl and coworkers reported significantly decreased 
cortisol levels during escitalopram and unchanged body 
composition established by magnetic resonance imaging 
(13). Depression is closely associated with the metabolic 
syndrome, where weight gain may prevail (34), but loss 
of appetite may also occur (35), and the effect of SSRI 
treatment on body composition is debated (35, 36). 
Previous studies reported increased (37, 38), unchanged 
(13, 36, 39) or decreased (40) waist circumference during 
treatment with SSRI in different study populations, 
Table 2 Mental health during treatment with escitalopram vs placebo.
  
All (n = 39)
Escitalopram (n = 20) Placebo (n = 19)
Pre-treatment 12 weeks Pre-treatment 12 weeks
WHO-5 well-being index 64 (43; 73) 64 (48; 72) 68 (61; 76) 56 (40; 76) 68 (52; 76)
Major depression inventory 14 (6; 23) 13 (7; 22) 12 (5; 17) 14 (5; 25) 5 (4; 11)
SF36
  PF: physical function 90 (85; 95) 90 (85; 95) 90 (85; 95) 90 (85; 95) 93 (85; 96)
  RP: role limitations physical 100 (75; 100) 100 (75; 100) 100 (75; 100)* 75 (75; 100) 100 (94; 100)
  BP: bodily pain 90 (68; 100) 90 (68; 100) 90 (58; 100) 90 (75; 100) 85 (65; 100)
  GH: general health 60 (50; 85) 60 (55; 70) 65 (55; 80) 65 (45; 85) 70 (55; 86)
  VT: vitality 55 (30; 70) 55 (30; 65) 60 (35; 80) 50 (34; 75) 71 (54; 75)
  SF: social function 100 (69; 100) 100 (63; 100) 100 (88; 100) 100 (69; 100) 100 (88; 100)
  RE: role limitations emotional 100 (50; 100) 100 (67; 100) 67 (67; 100) 83 (33; 100) 100 (67; 100)
  MH: mental health 76 (62; 84) 76 (60; 88) 80 (72; 88) 72 (62; 84) 84 (68; 12)
PCOS-Q
  PCOSQ emotion 4.3 (6.6; 5.1) 4.1 (3.4; 4.7) 5.0 (3.7; 5.8) 4.3 (3.6; 5.2) 4.6 (4.0; 5.8)
  PCOSQ body hair 2.8 (1.6; 4.6) 2.6 (1.6; 4.9) 2.8 (1.5; 5.0) 3.1 (2.1; 4.6) 3.0 (2.4; 4.6)
  PCOSQ weight 2.0 (1.2; 3.4) 2.2 (1.2; 3.2) 2.2 (1.4; 2.7) 1.8 (1.2; 3.4) 3.0 (2.0; 3.6)
  PCOSQ infertility problems 5.0 (3.5; 6.3) 4.3 (3.1; 5.9) 6.8 (4.1; 6.5) 5.4 (3.6; 6.3) 6.0 (3.8; 6.8)
  PCOSQ menstrual problems 4.3 (3.2; 5.5) 4.3 (3.3; 5.1) 5.0 (4.3; 5.5) 4.1 (3.1; 6.0) 4.8 (4.3; 6.0)
Data presented as median (quartiles).
*P < 0.05 ∆-SSRI vs ∆-placebo, Mann–Whitney U test for two samples.
Table 3 Multiple regression analyses.
 
Dependent variables
Independent variables
Pre-treatment cortisol# Medicine group ∆-Waist R2
∆-Cortisol 0 −0.5 (0.00)** 75 (0.10) −5.4 (0.48) 0.34 (0.002)*
∆-Cortisol 30 −0.6 (0.001)* 68 (0.08) −2.9 (0.65) 0.33 (0.003)*
∆-Cortisol 60 −0.3 (0.009)* 61 (0.04)* −0.03 (0.99) 0.28 (0.009)*
∆-Peak cortisol −0.3 (0.005)* 71 (0.03)* −1.5 (0.78) 0.30 (0.005)*
∆-AUC cortisol −0.5 (0.002)* 4007 (0.05) −1.4 (0.78) 0.29 (0.006)*
Pre-treatment cortisol# Medicine group ∆-BMI R2
∆-Cortisol 0 −0.5 (0.001)** 57 (0.18) 11.2 (0.55) 0.34 (0.002)*
∆-Cortisol 30 −0.5 (0.001)* 55 (0.08) 10.4 (0.52) 0.33 (0.002)*
∆-Cortisol 60 −0.3 (0.01)* 61 (0.03)* −0.83 (0.95) 0.28 (0.009)*
∆-Peak cortisol −0.4 (0.005)* 68 (0.03)* −1.2 (0.92) 0.30 (0.005)*
∆-AUC cortisol −0.4 (0.004)* 3394 (0.08) −511 (0.78) 0.24 (0.006)*
Predictors of changes in cortisol levels during intervention. Data presented as β-coefficient (P-value), *P < 0.05, **P < 0.001. Models regarding predictors 
of changes in cortisol 0, cortisol 30, cortisol 60, peak cortisol and AUC cortisol during intervention. Entered independent variables in each regression 
model: #pre-treatment value of each individual dependent variable (cortisol 0, cortisol 30, cortisol 60, peak cortisol, or AUC cortisol), medicine group (0 
placebo, 1 SSRI), and change in body composition (∆-waist or ∆-BMI).
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whereas we are not aware of data in PCOS. Previous 
publications pooled data from males and females (36, 
37, 38, 39, 40), which could have affected study results. 
Furthermore, in some papers, the type of SSRI may have 
affected the study outcome with escitalopram having a 
smaller (36) or a higher (38) effect on fat mass compared 
with other SSRIs. Even a small reduction in weight would 
have significant implications for PCOS phenotype and risk 
of diabetes and long-term data are needed to determine 
the effect of escitalopram on waist and body composition 
in PCOS. Changes in adrenal activity during escitalopram 
vs placebo were tested by comparing Δ-values between 
intervention groups. Interestingly, we found that women 
in the placebo group experienced lowering of cortisol 
levels during intervention, which could have affected 
significant findings of the present study. Our results could 
support that participating in a clinical trial may have a 
positive effect of adrenal activity and HRQol. Results 
of clinical trials without a placebo group should be 
interpreted with caution.
Changes in HRQoL were comparable between 
escitalopram and placebo in the present study, but the 
SF-36 domain, RP improved significantly during placebo 
vs escitalopram treatment. We found comparable changes 
in mental health (WHO-5 and MDI scores) between 
escitalopram and placebo, but the presence of low WHO-5 
scores decreased significantly during placebo, which 
supported a positive effect of trial participation. Side 
effects to SSRI treatment could affect mental health and 
patients’ emotions (41), but UKU was unchanged during 
study intervention, supporting that side effects did not 
affect our study outcomes. Women in the present study 
did not fulfill clinical criteria for depression, and it may 
be argued that out study population was ‘too healthy’ at 
baseline in comparison to studies performed on patients 
with clinical depression. The results of the present study 
were, however, in accordance with Knorr  et  al. (42), 
where changes in depression scores were similar between 
escitalopram and placebo in healthy relatives to patients 
with depression. Buhl did not report HRQol during 
treatment with escitalopram in healthy males with low 
birth weight (13), but the authors found no structural 
changes in the limbic brain morphology during study 
intervention. A recent meta-analysis on mental health 
during SSRI therapy found no placebo-controlled trials 
in patients with depression (43). The meta-analysis 
concluded that treatment with SSRI improved depression 
scores in patients with depression, but the clinical effect 
of improved depression scores was questionable and 
the risk of side effects and serious adverse events during 
SSRI was increased (43). These results were, however, 
questioned due to unclear definition of side effects and 
omission of clinical trials from the meta-analysis (44). 
Escitalopram treatment is not registered for treatment of 
patients without clinical depression, and our data support 
that escitalopram is not effective in treating impaired 
HRQol in PCOS. More studies are needed regarding the 
effect of escitalopram in women with PCOS and clinical 
depression.
Measures of insulin resistance were unchanged 
during escitalopram in the present study. Escitalopram 
is an inhibitor of 5-hydroxytryptamine and stimulates 
serotonergic activity. Increased serotoninergic activity 
was associated with increased insulin sensitivity (45). In 
accordance, glycemic control was improved in patients 
with type 2 diabetes during treatment with SSRI (15) 
and insulin sensitivity increased in non-diabetic study 
populations (13, 37, 40). The median BMI of our study 
population was 33 kg/m2 and the participants had high 
fasting insulin levels, supporting an insulin resistant PCOS 
phenotype. Our study could be underpowered to detect 
small changes in insulin sensitivity during escitalopram, 
but we found no improvement of PCOS characteristics 
including cycle regularity, which further supported that 
escitalopram did not improve insulin sensitivity to any 
clinically relevant extent. Furthermore, we found no 
changes in lipid levels during escitalopram. Previously, 
there have been reports on changes in TG in non-PCOS 
populations during SSRI (35, 36, 40, 46). However, findings 
were not uniform as some authors reported increased (35, 
46), decreased (40) or unchanged (36) TG levels during 
escitalopram treatment. None of these studies reported 
data on women alone and various patient populations and 
types of antidepressants were included in the studies (35, 
36, 40, 46). SSRI treatment could stimulate α1 receptors 
in fat tissue and enhance lipolysis (47). In accordance, 
a microdialysis study showed acute release of glycerol 
and free fatty acids from the subcutaneous fat tissue 
during treatment with escitalopram (47). Furthermore, 
changes in lipid status could be secondary to changes 
in weight, insulin sensitivity or HPA axis activity. Our 
finding of unchanged metabolic status during treatment 
with escitalopram is reassuring given common use of 
antidepressive treatment in PCOS (4, 6).
Strengths and limitations may apply to the present 
study. The study was randomized, placebo-controlled, 
double-blinded, and participants were thoroughly 
evaluated in one single medical center. It was not possible 
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to do a power calculation and the present study should 
therefore be considered a pilot study. Adrenal activity 
was evaluated by ACTH test performed in the morning, 
but the study results could have been strengthened 
by adding 24-h s-cortisol profiles or measurement of 
urinary cortisol excretion. We used a combination of 
disease-specific and generic questionnaires to describe 
HRQoL. Measures of insulin sensitivity were calculated 
at fasting and by measures derived from 3-h OGTT. 
The euglycemic–hyperinsulinemic clamp is the golden 
standard to measure insulin sensitivity, but the present 
study did not support any clinical relevant changes in 
glucose tolerance, insulin sensitivity or insulin secretion 
after escitalopram treatment. Our study design could 
have been improved by adding measurements of free fatty 
acids and inflammatory markers such as adiponectin or 
interleukins.
We included overweight and obese women with PCOS 
and our study results may not apply in lean women with 
PCOS. Furthermore, different study results may be found 
in women with PCOS and major depression.
In conclusion, treatment with escitalopram increased 
cortisol levels and waist circumference in women with 
PCOS and no clinical depression, whereas mental health 
and measures of insulin resistance were unchanged. More 
studies are needed to determine long-term metabolic and 
clinical outcomes after SSRI treatment in other PCOS 
phenotypes and in women with PCOS and depression.
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